Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 302, Issue 1, 2002, Pages 381-389

  Burris, Kevin D ^a   Molski, Thaddeus F ^a   Xu, Cen ^a   Ryan, Elaine ^b   Tottori, Katsura ^b   Kikuchi, Tetsuro ^a   Yocca, Frank D ^a   Molinoff, Perry B ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHOXY 1(2H) QUINOLINECARBOXYLIC ACID ETHYL ESTER; 7 HYDROXY 2 (N,N PROPYL N 3' IODO 2' PROPENYL)AMINOTETRALIN; ARPIPRAZOLE; BUTACLAMOL; CYCLIC AMP; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PARTIAL AGONIST; PRECLAMOL; QUINPIROLE; RADIOLIGAND; RECEPTOR RESERVE; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; SPIPERONE; TERGURIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; SEROTONINERGIC SYSTEM;

1-METHYL-3-ISOBUTYLXANTHINE; ANIMALS; ANTIPSYCHOTIC AGENTS; CHO CELLS; CRICETINAE; CYCLIC AMP; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; FORSKOLIN; GTP-BINDING PROTEINS; HUMANS; PIPERAZINES; QUINOLONES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION; SPIPERONE;

EID: 0036089687     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.033175     Document Type: Article

References (44)

1. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus
2. Differential coupling of rat D2 dopamine receptor isoforms expressed in Spodoptera frugiperda insect cells
3. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
4. Lack of discrimination by agonists for D2 and D3 dopamine receptors
5. Meta-analysis of safety and tolerability with aripiprazole
6. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction
7. (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis
8. The elusive nature of intrinsic efficacy
9. Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists
10. Paradoxical regulation of dopamine receptors in transfected 293 cells
11. L dopamine receptors by agonists and antagonists in transfected HEK-293 cells
12. Comparison of dissociation constants and of relative efficacy of selected agonists acting on parasympathetic receptors
13. Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins
14. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline
15. Partial agonists, full agonists, antagonists: Dilemmas of definition
16. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum
17. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyllbutyloxy)-3,4-dihydro-2(1H) -quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland
18. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
19. Efficacy of aripiprazole in psychotic disorders: Comparison with haloperidol and placebo
20. Transdihydrolisuride, a partial dopamine receptor antagonist: Effects on monoamine metabolism
21. Efficacy in drug receptor theory: Outdated concept or under-valued tool
22. Relative efficacy of prenalterol and pirbuterol for beta-1 adrenoceptors: Measurement of agonist affinity by alteration of receptor number
23. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H) -quinolin-one (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity
24. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia
25. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: Utilization of receptor state binding affinities
26. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes
27. Relationship between receptor occupancy and response at striatal dopamine autoreceptors
28. Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity
29. Receptor reserve for D2 dopaminergic inhibition of prolactin release in vivo and in vitro
30. Developing novel antipsychotic drugs: Strategies and goals
31. Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area
32. Receptor occupancy and tissue response
33. Aripiprazole, a new atypical antipsychotic: Phase II clinical trial results
34. Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder
35. The attractions of proteins for small molecules and ions
36. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain
37. The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins
38. Distinct functions of the two isoforms of dopamine D2 receptors
39. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions
40. Dopamine autoreceptor agonists in the treatment of schizophrenic disorders
41. The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland
42. Influence of G protein type on agonist efficacy
43. Effect of guanine nucleotides on striatal dopamine receptors